Roll over image to zoom in
lenvanix 4 (lenvatinib) 4mg online
$349.00
Status: In stock
Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic
Lenvanix (lenvatinib) is a kinase inhibitor that is indicated for:
1.Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
2.Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
3.Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma
DOSAGE AND ADMINISTRATION
1.Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.
2.Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.
3.Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma
DOSAGE AND ADMINISTRATION
- Recommended dose (DTC): 24 mg orally, once daily.
- Recommended dose (RCC): 18 mg lenvatinib + 5 mg everolimus, orally, once daily.
- Recommended dose (HCC): 12 mg orally, once daily (for adults weighing >_60 Kg). 8 mg orally, once daily for adults weighing
Related products
Recently Viewed Products
